Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: arcturusrx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/12/2024 | $70.00 | Outperform | Leerink Partners |
12/13/2023 | $90.00 | Buy | Canaccord Genuity |
7/24/2023 | $71.00 | Outperform | William Blair |
5/11/2023 | $19.00 → $51.00 | Neutral → Buy | H.C. Wainwright |
11/14/2022 | $35.00 | Overweight | Wells Fargo |
11/10/2022 | $18.00 | Neutral → Underperform | Robert W. Baird |
11/3/2022 | $22.00 → $35.00 | Neutral → Buy | Citigroup |
11/2/2022 | $16.00 → $25.00 | Underweight → Equal Weight | Barclays |
8/10/2022 | Mkt Perform → Underperform | Raymond James | |
7/19/2022 | $86.00 → $39.00 | Overweight | Cantor Fitzgerald |
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
S-8 - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
144 - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
144 - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
144 - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
144 - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, including rare diseases. Dr. Sutherland is a pulmonologist by training with deep clinical knowledge combined with R&D and corporate strategy leadership across pulmonary and rare diseases. In connection with
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005321/en/Jing L Marantz, M.D., Ph.D., M.B.A. (Photo: Business Wire) "We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board," said Joseph Payne, President &
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences: Wells Fargo 2024 Healthcare Conference (Fireside Chat) Wednesday, September 4, 2024 (3:00 p.m. ET) RNA Leaders USA Conference (Presentation) Thursday, September 5, 2024 (2:15 p.m. ET) H.C. Wainwright 26th Annual Global Investment Conference (Presentation) Monday, September 9, 2024 (11:00 a.m. ET) Cantor Fitzgerald An
IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. "We are pleased to remain on track for our first commercial product launch of Ko
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the Company will present at Canaccord Genuity 44th Annual Growth Conference in Boston, on Tuesday, August 13, 2024, at 9:30 am Eastern Time. A webcast and replay of the presentation will be available on the "Investor Relations/Events" section of the Company's website at: https://ir.arcturusrx.com/investor-calendar. About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus T
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 5, 2024. Arcturus Therapeutics Second Quarter 2024 Earnings Conference Call Monday, August 5, 2024 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13747924 Web
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitted in the next 60 days Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (O
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm
ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF) Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trikafta® Early trend of improved lung function with an average absolute response of +4.0% (ranging up to +9%) and relative change of +5.8% FEV1 on Day 8, after two doses of ARCT-032 Clinical data is consistent with pre-clinical CF ferret model data Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two administrations Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to treat CF, at
Combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal
Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster. Global biotechnology leader CSL ((ASX:CSL, OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price target.
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe diseaseARCT-032 IND for Phase 2 multiple ascending dose study to be submitted in the next 60 daysArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) defici
On Tuesday, June 25, 2024, Cathie Wood-led Ark Invest made significant trades in NVIDIA Corp (NASDAQ:NVDA) and Roku Inc (NASDAQ:ROKU), amidst considerable market volatility. These trades were part of a series of transactions carried out by Ark’s various ETFs. The NVIDIA Trade The firm’s ARK Autonomous Technology & Robotics ETF (BATS:ARKQ) sold 33,834 NVIDIA shares on Tuesday. The transaction was valued at $4.3 million. On the day, Nvidia shares closed 6.8% higher at $126.09. This move comes in the wake of a significant market cap loss for the tech giant, which saw a $550 billion drop since Thursday. Despite this, NVIDIA managed to rebound by over 6% on Tuesday, regaining its positio
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM). The Robinhood Trade Ark Invest sold 64,706 shares of Robinhood, valued at approximately $1.53 million, through the Ark Fintech Innovation ETF (NYSE:ARKF) and ARK Next Generation Internet ETF (NYSE:ARKW). This move comes after the company recently reduced its holdings in Robinhood amid market fluctuations. The company’s shares are currently trading higher following the announcement of its May operating data. Notably, the Robinhood trade took place on a day Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) saw some uptrend but
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio. The HOOD Trade: Ark Invest’s decision to trim its position in Robinhood was executed through three of its ETFs. The ARK Fintech Innovation ETF (NYSE:ARKF) sold 31,827 shares, while the ARK Innovation ETF (NYSE:ARKK) and the ARK Next Generation Internet ETF (NYSE:ARKW) offloaded 215,675 and 76,299 shares respectively. Based on Robinhood’s closing price of $23.42 on Monday, the total value of the shares sold is approximately $7.6 mill
Friday, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled investigational mRNA therapeutic, at the European Cystic Fibrosis Conference. ARCT-032 administration was generally safe and well tolerated, with no serious or severe adverse events in healthy volunteers and the first four dosed participants with cystic fibrosis. The Phase 1b trial showed improvements in FEV1 (Forced Expiratory Volume in 1 second) in the four adults with cystic fibrosis after two inhaled administrations. The absolute change in percent predicted FEV1 averaged +4.0% on Day 8 (5 days a
Gainers Venus Concept (NASDAQ:VERO) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. Asensus Surgical (AMEX:ASXC) stock moved upwards by 41.22% to $0.33. The market value of their outstanding shares is at $90.3 million. American Oncology Network (NASDAQ:AONC) shares rose 29.41% to $2.2. The market value of their outstanding shares is at $22.4 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares rose 29.33% to $2.8. The market value of their outstanding shares is at $72.6 million. IN8bio (NASDAQ:INAB) stock increased by 22.12% to $1.38. The market value of their outstanding shares is at $60.8 million. Geron (NASDAQ:GERN) stock
ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF)Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trikafta®Early trend of improved lung function with an average absolute response of +4.0% (ranging up to +9%) and relative change of +5.8% FEV1 on Day 8, after two doses of ARCT-032Clinical data is consistent with pre-clinical CF ferret model data
On Tuesday, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced that it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in cystic fibrosis (CF) for ARCT-032 at the European Cystic Fibrosis Conference. “We were pleased to observe ARCT-032 treatments for the first four patients were generally safe and well tolerated with no serious adverse events,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “Furthermore, we observed an encouraging trend towards lung function improvements in the first four CF participants after only two inhaled administrations.” “The absolute change in percent predicted FEV1 (Forced Expiratory Volume in 1 second)
IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. "We are pleased to remain on track for our first commercial product launch of Ko
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 5, 2024. Arcturus Therapeutics Second Quarter 2024 Earnings Conference Call Monday, August 5, 2024 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13747924 Web
Commercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3 Kostaive® European Marketing Authorization Application approval decision expected Q3 Multiple Kostaive® Phase 3 trials further demonstrate breadth and durability of STARR® vaccine platform ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3 ARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1st JP Morgan engaged to monetize investment in ARCALIS JV in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messe
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024. Arcturus Therapeutics First Quarter 2024 Earnings Conference Call Wednesday, May 8, 2024 @ 4:30 p.m. ET Domestic: 1-888-886-7786 International: 1-416-764-8658 Conference ID: 96934019 Webcast: Link About Arcturus
Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea Cash runway extended to Q1 2027 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2023 after the market close on Thursday, March 7 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 7, 2024. Arcturus Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call Thursday, March 7, 2024 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8
Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial Enrollment initiated in ARCT-032 Phase 1b study; dosing first cystic fibrosis patient this month ARCT-032 received Rare Pediatric Disease Designation for cystic fibrosis from the FDA Investor conference call at 4:30 p.m. ET November 14, 2023 Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2023 after the market close on Tuesday, November 14 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 14, 2023. Arcturus Therapeutics Third Quarter 2023 Earnings Conference Call Tuesday, November 14, 2023 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conferen
ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profile Meiji Seika Pharma submitted ARCT-154 New Drug Application in Japan New ARCT-154 booster clinical data demonstrate one-year durability across a panel of variants Received FDA Fast Track Designation and Rare Pediatric Disease Designation for ARCT-810 for OTC deficiency Received regulatory approval of ARCT-032 to proceed into a Phase 1b clinical study in CF patients Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company, " "Arcturus, NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company f
Arcturus to present at the Canaccord Genuity 43rd Annual Growth Conference, August 9, 2023 Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will release its financial results for the quarter and six months ended June 30, 2023 after the market close on Monday, August 7th and will also host a conference call and webcast at 4:30 p.m. Eastern Time on August 7th, 2023. The Company also announced it will present at the Canaccord Genuity 43rd
Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00
Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00
William Blair initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $71.00
H.C. Wainwright upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $51.00 from $19.00 previously
Wells Fargo resumed coverage of Arcturus Therapeutics with a rating of Overweight and set a new price target of $35.00
Robert W. Baird downgraded Arcturus Therapeutics from Neutral to Underperform and set a new price target of $18.00
Citigroup upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $35.00 from $22.00 previously
Barclays upgraded Arcturus Therapeutics from Underweight to Equal Weight and set a new price target of $25.00 from $16.00 previously
Raymond James downgraded Arcturus Therapeutics from Mkt Perform to Underperform
Cantor Fitzgerald resumed coverage of Arcturus Therapeutics with a rating of Overweight and set a new price target of $39.00 from $86.00 previously